INTRODUCTION

A World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) reviewed in 2017 the evidence of the effectiveness of the Bacillus of Calmette and Guérin (BCG) vaccine, a biologic prepared to prevent tuberculosis infection, in the prevention of leprosy [1]. Based on the evidence of a meta-analysis [2] that included data from 5 randomized trials, 6 cohort studies and 17 case-control studies with a pooled 59% effectiveness (95% confidence interval [CI], 34 to 84), the 2017 WHO SAGE report concluded that “in comparison to the effectiveness of BCG against tuberculosis, BCG seems to be more protective against leprosy” [1]. As noted in the same report, a BCG trial conducted in Bangladesh reported in 0.4% of contacts receiving the vaccine developed clinical leprosy within 12 weeks of the immunization with BCG [3]. A recent survey conducted by the WHO Global Leprosy Program found that few leprosy-endemic countries have adopted the use of BCG or revaccination of contacts of leprosy cases, including Brazil, Colombia and Peru in the Americas [4].

The occurrence of leprosy in Paraguay has decreased considerably with detection rates cut by half, between 2005 (8.3 detected cases per 100,000 population) and 2016 (5.0 detected cases per 100,000 population) (Figure 1) [5]. Leprosy occurs at higher rates

OBJECTIVES: Paraguay has experienced a 35% reduction in the detected incidence of leprosy during the last ten years, as the vaccination coverage against tuberculosis (Bacillus of Calmette and Guérin [BCG] vaccine) reached ≥ 95% among infants. The objective of this case-control study was to evaluate the protective effect of BCG on the risk of leprosy.

METHODS: We used a population-based case-control study of 20 leprosy confirmed cases reported among residents of Ciudad del Este, Paraguay, diagnosed in 2016-2017. Three controls were selected from a random sample of households from the city. We assessed vaccine effectiveness using 1- odds ratio [OR], and confounding for age, gender, education, occupation, and marital status using stratified and exact logistic regression, and explored if there was effect modification calculating the synergy factor (SF) and relative excess risk due to interaction (RERI).

RESULTS: After controlling for age, gender, education, occupation and marital status, the OR of BCG scar on the risk of leprosy was 0.10 (95% confidence interval [CI], 0.02 to 0.45), for an estimate of vaccine effectiveness of 89.5% reduced risk of leprosy (95% CI, 55.2 to 98.1). There was evidence of heterogeneity by which the effectiveness of BCG seemed stronger among younger persons (Breslow-Day and Z-test of the SF had a p < 0.05), and both the RERI and SF indicated a less then multiplicative and additive interaction of BCG and younger age.

CONCLUSIONS: BCG vaccination was associated with a decreased risk of leprosy in the study population, particularly in persons born after 1980.

KEY WORDS: Leprosy, BCG vaccine, Case-control studies, Epidemiologic studies, Prevention and control, Paraguay
in states that border Brazil where the detection rates are > 10 per 100,000 population [6-8]. In Paraguay, the BCG vaccination started in 1978 [9], targeted newborns at birth and covered all children under 5 years if they had not received the vaccine at birth [10], using vaccines obtained through consolidated purchases of the Pan American Health Organization, or donations from United Nations Children’s Fund, manufactured mostly from the following strains: Pasteur 1173 P2, Statens Serum Institut of Denmark 1331, Glaxo-Evans 1077, and Tokyo 172 [10]. The coverage of BCG vaccination has steadily increased since the 1990s [11]. The 1990 Demographic and Health Survey found a 44% coverage among infants lower than the reported coverage of 75% for the same year [12]. Although the reported figures might overestimate the vaccination coverage, the pattern is consistent with an increasing coverage to nearly universal levels by the 2005 (Figure 1) [5].

Although Brazil bears 12% of the burden of newly detected cases of leprosy in world, in the WHO Region of the Americas, Paraguay comes third behind Brazil and Guyana in terms of detected cases per 100,000 population in 2016 [6]. However, no previous studies on BCG and leprosy were conducted before in Paraguay. We reviewed the scientific literature using an Ovid MEDLINE for the period 1946 and the week ending on June 5, 2021, searching the terms BCG vaccine and leprosy in combination with clinical trials, experimental studies in humans, cohort, case-control, cross-sectional and ecologic or epidemiologic studies and found 111 references, from which 30 were epidemiologic studies, and none of them was conducted in Paraguay. We carried out a case-control study to assess the effectiveness of BCG in Ciudad del Este, Paraguay in 2016-2017.

MATERIALS AND METHODS

Study design and population

We conducted an unmatched population-based case-control study using three controls per case in Ciudad del Este (301,815 population), the second largest city in Paraguay. It is located across the border with Brazil and Argentina. The city is close to the Itaipu dam and is free-trade zone that attracts tourists and is the international Friendship Bridge crosses the Paraná River connecting Foz de Iguazú, Brazil and Ciudad del Este, with 70,000 crossings every day.

Case definition

Cases included were all microscopy confirmed cases of leprosy from January 1, 2016 to July 31, 2017, among residents of Ciudad del Este. All cases were classified according to Ridley and Jopling criteria based on their medical records. All cases were 14 years of age or older.

Control definition and selection

Controls were residents of Ciudad del Este selected at random as described below, who were at least 14 years of age and who were cognitively able to provide consent. We obtained parental consent for those 14-18 years of age. The controls were selected in a random sample of blocks of Ciudad del Este, using the most recent cartography available at the district office of the Ministry of Health as sampling framework. We selected 30 blocks with probability proportional to size of the blocks, and from each selected city block a starting point was selected at random. Then we visited as many consecutive households walking in eastward direction from the starting point to identify, obtain verbal informed consent and recruit into the study three consenting persons as controls from different households, using the next birthday method. There were no refusals among cases or the potential controls.

Data collection

One of the authors (NCC) approached all cases and potential controls in June 2017. She invited potential participants to take part in the study and obtained informed written consent. Potential controls were asked if they had ever been diagnosed or told they had leprosy. Both cases and controls were asked if they had received the BCG vaccine and were asked to show their upper arms for presence of a BCG scar.

Data analysis and sample size

We compared cases and controls for the odds of the presence of BCG scar as well as by age, gender, marital status, last school grade completed, occupation, and contact with a leprosy case, forming dichotomous variables to make the comparisons more stable. We tested the null hypothesis the presence of BCG scar was not associated with the risk of leprosy, i.e., the odds ratio (OR) was 1. We estimated the OR and its 95% confidence interval (CI) and conducted stratified and exact logistic regression analysis that simultaneously controlled for the following potential confounders, age, gender, marital status, education and occupation and examined the presence of heterogeneity using the Breslow and Day test [13]. We estimated the vaccine effectiveness subtracting the OR from 1 [14]. For factors showing a statistically significant heterogeneity, we calculated the relative excess risk for interaction (RERI) in the
additive scale [15], and the synergy factor (SF) for the multiplicative scale to measure effect modification [16]. Both measures consider subjects with none of the exposures as referent (OR₀₀), the OR for the exposure to the two factors combined (OR₁₁) we: (1) subtract (additive scale) the ORs for the presence of one of them in the absence of the other (i.e., OR₀₁, OR₁₀), or (2) divide OR₁₁ by the product of OR₀₁ and OR₁₀ (multiplicative scale). The 95% CI and the statistical significance of RERI and SF was computed using a method to estimate variance recovery [17] and a standard normal approximation [16], respectively.

Based on preliminary observations of one of the authors (VMC), of a BCG coverage of 80% and assuming the true OR was 0.2 (i.e., BCG effectiveness of 80%), we planned a study with 20 cases and 60 controls. We anticipated such study will be able to reject the null hypothesis that this OR equals 1.0 with probability (power) of 82.6%. The type I error probability α, associated with this test of this null hypothesis was 0.05.

All data analysis were carried out using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). We calculated 95% CIs around the OR, RERI and SF. Statistical significance was specified as two-sided α = 0.05.

**Ethics statement**

The study protocol was approved by the Institutional Review Board (IRB) of the Faculty for Health Sciences at (Paraguay) National University of the East approved the study (IRB No. # 0401-2019). Informed consent was confirmed by the IRB.

**RESULTS**

In 2010-2016 an average of 15 newly detected cases of leprosy have been reported in Ciudad del Este. The detection rate of cases of leprosy in 2016 was 4.9 per 100,000. In 2016, and through June 2017, 20 cases were reported, and all 20 potentially eligible cases and controls agreed to take part in the study. Eleven (55.0%) of the cases were lepromatous leprosy and nine (45.0%) were borderline lepromatous leprosy. Seventy percent were multibacillary. The characteristics of the cases and controls are presented on Table 1. There were no significant differences by age, gender, marital status, schooling, or occupation. However, 2/20 (10.0%) of the cases had a history of contact with a relative known to be a case of leprosy, and such difference was borderline statistically significant (p = 0.006), but none of the controls with undefined estimates of the OR and we decided to leave this variable out of the remaining analyses. The most striking difference was on the presence of BCG scar: OR, 0.2; 95% CI, 0.1 to 0.5; p = 0.001). The unadjusted vaccine effectiveness was estimated as 1- OR: or 1 - (0.17) = 83%; 95% CI, 49% to 94%. The protective effect did not change meaningfully (i.e., > 10%) when controlled by age (OR₁₁,= 0.2), or gender (OR₁₁,= 0.2), education (OR₁₁,= 0.2), or occupation (OR₁₁,= 0.2), and only slightly by and marital status (OR₁₁,= 0.1). An exact logistic model that simultaneously adjusted for all five covariates, resulted in an estimate of the OR of 0.1 (95% CI, 0.0 to 0.4).

We also found evidence that the effectiveness of BCG varied by age (Table 2). The OR among those less than 40 years of age was 0.0 (95% CI, 0.0 to 0.2), while for those 40 years of age and older was 0.4 (95% CI, 0.1 to 2.0). The p-value of the Breslow-Day for the homogeneity of the OR was 0.03, indicating that the difference by age was statistically significant. Using those without BCG and 40 years of age or older as referent, the OR for the combination of age and BCG shows a reduced risk of leprosy among persons under 40 years of age vaccinated (OR, 0.2), a decreased the risk of leprosy among those with BCG scar and 40+ years (OR, 0.4), an increased risk of leprosy for those younger than 40 without the BCG (OR, 7.0). The SF less than one (i.e., 0.07), implies an effect modification by which the presence of both younger age and BCG resulted in increased protection against leprosy: the actual effectiveness of BCG was 93% in this age group. Conversely, even though 50% of the older controls had a BCG scar, the effectiveness was only 60%. The p-value associated with a normal distribution test showed the positive interaction of BCG with younger age was statistically significant (p < 0.05), consistent with the Breslow-Day test, and the 95% CI for the SF did not include the null value (i.e., 1.0) (SF: 95% CI, 0.01 to 0.87). Not surprising, there was also a

| Characteristics | Case (n=20) | Control (n=60) | OR (95% CI) | p-value |
|-----------------|------------|---------------|-------------|---------|
| Age (mean), yr  |            |               |             |         |
| 14-39           | 10 (50.0)  | 30 (50.0)     | 1.0 (reference) | >0.99   |
| 40-79           | 10 (50.0)  | 30 (50.0)     | 1.0 (0.4, 2.7) |         |
| Gender          |            |               |             |         |
| Men             | 13 (65.0)  | 28 (46.7)     | 2.1 (0.7, 6.1) | 0.20    |
| Women           | 7 (35.0)   | 32 (53.3)     | 1.0 (reference) |         |
| Marital status  |            |               |             |         |
| Married/living  | 13 (65.0)  | 30 (50.0)     | 1.9 (0.7, 5.3) | 0.30    |
| with a partner  |            |               |             |         |
| Single/widowed  | 7 (35.0)   | 30 (50.0)     | 1.0 (reference) |         |
| divorced        |            |               |             |         |
| Education       |            |               |             |         |
| ≤6th grade      | 10 (50.0)  | 25 (41.7)     | 1.4 (0.5, 3.9) | 0.60    |
| >6th grade      | 10 (50.0)  | 35 (58.3)     | 1.0 (reference) |         |
| Occupation      |            |               |             |         |
| Unemployed/street vendor | 2 (10.0) | 3 (5.0) | 2.1 (0.3, 13.6) | 0.60    |
| Other           | 18 (90.0)  | 57 (95.0)     | 1.0 (reference) |         |
| Living with someone with leprosy | | | | |
| Yes             | 2 (10.0)   | 0 (0.0)       | ∞ (0.9, ∞) | 0.006   |
| No              | 18 (90.0)  | 60 (100)      | 1.0 (reference) |         |
| BCG scar        |            |               |             |         |
| No              | 14 (70.0)  | 17 (28.3)     | 1.0 (reference) | 0.001   |
| Yes             | 6 (30.0)   | 43 (71.7)     | 0.2 (0.1, 0.5) |         |

Values are presented as number (%).

BCG, Bacillus of Calmette and Guérin.

Cuevas NC et al. : BCG and leprosy in Paraguay
and previous studies have reported higher effectiveness of BCG against this form of leprosy [19,25].

Our estimate of effectiveness is similar to those of most epidemiologic studies, including field trials [20,22,23,26-31], cohort studies [23,29,32-35], case-control studies [18,19,36-48], most of them summarized in a meta-analysis [2].

Limitations
We did not include participants under 14 years of age in our study, as there were no cases under that age, which limits the generalizability to incidence in older children and adults in Paraguay. Although known cases of leprosy under 14 years of age are rare, they could also be overlooked. The leprosy program could be under diagnosing paucibacillary leprosy; however, it may happen in both Paraguay and Brazil, as the proportion of paucibacillary cases was similar in Foz de Iguazú [9]. Our study was small and was not planned to fully assess the effect modification of the age of the participants of the effectiveness of the BCG vaccination. It is unlikely that there has been any shift in quality of BCG since the vaccines strains of four laboratories have accounted for about 90% of BCG supplies over time, and no differences in effectiveness have been found across them. The differences are unlikely explained just by chance, but future larger studies, specifically designed to assess the interaction of age and BCG in the multiplicative scale, requiring about 320 cases and 960 controls, if using a 1:3 ratio to maximize the statistical power, assuming the same age distribution, and coverage of BCG (70%) as found in the study population, are needed [49]. Further studies are needed in Paraguay, possibly assessing use of BCG and rifampin among contacts.

In conclusion, this small study confirms the potential impact of BCG vaccination to prevent leprosy. We recommend exploring the adoption of strategies in place in Brazil that complements multidrug therapy with contact tracing and BCG targeted booster vaccination.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare for this study.

FUNDING
None.

ACKNOWLEDGEMENTS
None.

AUTHOR CONTRIBUTIONS
Conceptualization: NCC, VMC. Data curation: NCC, VMC. Formal analysis: VMC, NCC. Funding acquisition: None. Methodology: VMC, NCC. Project administration: NCC, VMC. Visu-
ORCID

Nancy Carolina Cuevas: https://orcid.org/0000-0001-6800-8015
Victor M. Cardenas: https://orcid.org/0000-0002-7951-0980

REFERENCES

1. World Health Organization. Strategic Advisory Group of Experts on immunization (SAGE)- October 2017 [cited 2021 Jul 14]. Available from: https://www.who.int/news-room/events/detail/2017/10/17/default-calendar/strategic-advisory-group-of-experts-on-immunization-(sage)--october-2017.

2. Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010;9:209-222.

3. Richardus RA, Butlin CR, Alam K, Kundu K, Geluk A, Richardus JH. Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh. Vaccine 2015;33:1562-1567.

4. Gillini L, Cooreman E, Wood T, Pemmaraju VR, Saunderson P. Global practices in regard to implementation of preventive measures for leprosy. PLoS Negl Trop Dis 2017;11:e0005399.

5. World Health Organization. Global health observatory data. Lepero- 2015. Available from: https://orcid.org/0000-0001-6800-8015.

6. Ajalla ME, Andrade SM, Tamaki EM, Waissmann W, Diettrich SH, Silva BA. The context of leprosy in Brazil-Paraguay border. Cien Saude Colet 2016;21:225-232.

7. Ajalla ME, Oliveira De Andrade SM, Tamaki EM, Waissmann W, Diettrich SH, Aragão Do Nascimento V. Leprosy in Brazilian counties bordering Paraguay: Mato Grosso do Sul State, 2001-2011. Lepr Rev 2016;87:32-41.

8. Simionato de Assis I, Arcoverde MA, Ramos AC, Alves LS, Berra TZ, Arroyo LH, et al. Social determinants, their relationship with leprosy risk and temporal trends in a tri-border region in Latin America. PLoS Negl Trop Dis 2018;12:e0006407.

9. Gimenez-León P, Ramirez de Rojas ME. History of public health planning in Paraguay 1956-2015 [cited 2021 Aug 17]. Available from: http://www.rissalud.net/images/pdfpublicos/historia_planificacion.pdf (Spanish).

10. Ministry of Public Health and Welfare. Technical report on the Expanded Program on Immunizations, January 2016 [cited 2021 Aug 17]. Available from: https://paraguay.bvsalud.org/wp-content/uploads/2018/11/normasdelpais2016selection1.pdf (Spanish).

11. World Health Organization. BCG immunization coverage among one-year-olds (%); 2021 [cited 2021 Dec 20]. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hem-bcg-immunization-coverage-among-one-year-olds-1.

12. Institute for Resource Development/Macro Systems, Inc. Demographic and Health Surveys 1990 [cited 2021 Jul 14]. Available from: https://dhsprogram.com/pubs/pdf/FR30/FR30.pdf (Spanish).

13. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - the analysis of case-control studies. IARC Sci Publ 1980: 5-338.

14. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988;10:212-241.

15. Rothman KJ, Greenland S. Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008, p. 299.

16. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2009;2:105.

17. Zou GY. On the estimation of additive interaction by use of the four-by-two table and beyond. Am J Epidemiol 2008;168:212-224.

18. Rodrigues LC, Kerr-Pontes LR, Frietas MV, Barreto ML. Long lasting BCG protection against leprosy. Vaccine 2007;25:6842-6844.

19. Zodpey SP, Ambadekar NN, Thakur A. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health 2005;119:209-216.

20. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17-24.

21. Araujo S, Rezende MM, Sousa DC, Rosa MR, Santos DC, Goulart LR, et al. Risk-benefit assessment of Bacillus Calmette-Gué- rin vaccination, anti-phenolic glycolipid I serology, and Mitsuda test response: 10-year follow-up of household contacts of leprosy patients. Rev Soc Bras Med Trop 2015;48:739-745.

22. Convit J, Sampson C, Zúñiga M, Smith PG, Plata J, Silva J, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992; 339:446-450.

23. Gomes RR, Antunes DE, Dos Santos DF, Sabino EF, Oliveira DB, Goulart IM. BCG vaccine and leprosy household contacts: protective effect and probability to becoming sick during follow-up. Vaccine 2019;37:6510-6517.

24. Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study in south India. Indian J Lepr 1998;70:369-388.

25. Brown JA, Stone MM, Sutherland I. B.C.G. vaccination of children against leprosy in Uganda: results at end of second follow-up. J Hyg (Lond) 1981;87:233-248.

26. Brown JA, Stone MM, Sutherland I. B.C.G. vaccination of children against leprosy in Uganda: final results. J Hyg (Lond) 1981;87:233-248.

27. Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study in south India. Indian J Lepr 1998;70:369-388.

28. Gupte MD, Vallishayee RS, Anantharaman DS, Nagaraju B, Sreevatsa, Balasubramanyam S, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr 1998;70:369-388.
29. Chaudhury S, Hazra SK, Saha B, Mazumder B, Biswas PC, Chattopadhyay D, et al. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis. Int J Lepr Other Mycobact Dis 1994;62:389-394.

30. Bagshawe A, Scott GC, Russell DA, Wigley SC, Merianos A, Berry G. BCG vaccination in leprosy: final results of the trial in Kairimu, Papua New Guinea, 1963-79. Bull World Health Organ 1989;67:389-399.

31. Lwin K, Sundaresan T, Gyi MM, Bechelli LM, Tamondong C, Garbajosa PG, et al. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull World Health Organ 1985;63:1069-1078.

32. Pönnighaus JM, Fine PE, Sterne JA, Wilson RJ, Msoa E, Gruer PJ, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992;339:636-639.

33. Fine PE, Pönnighaus JM, Maine N, Clarkson JA, Bliss L. Protective efficacy of BCG against leprosy in Northern Malawi. Lancet 1986;2:499-502.

34. Düppre NC, Camacho LA, da Cunha SS, Struchiner CJ, Sales AM, Nery JA, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008;102:631-638.

35. Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Gonçalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol 2008;15:101-105.

36. Convit J, Smith PG, Zuniga M, Sampson C, Ulrich M, Plata JA, et al. BCG vaccination protects against leprosy in Venezuela: a case-control study. Int J Lepr Other Mycobact Dis 1993;61:185-191.

37. Rahete NP, Zodpey SP, Shrikhande SN, Salodkar AD, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev 1999;70:287-294.

38. Zodpey SP, Shrikhande SN, Salodkar AD, Maldhure BR, Kulkarni SW. Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy: a case-finding control study in Nagpur, India. Int J Lepr Other Mycobact Dis 1998;66:309-315.

39. Lombardi C, Pedrazzani ES, Pedrazzani JC, Filho PF, Zicker F. Protective efficacy of BCG against leprosy in São Paulo. Bull Pan Am Health Organ 1996;30:24-30.

40. Boelens JJ, Kroes R, van Beers S, Lever P. Protective effect of BCG against leprosy in South Sulawesi, Indonesia. Int J Lepr Other Mycobact Dis 1995;63:456-457.

41. Thuc NV, Abel L, Lap VD, Oberti J, Lagrange PH. Protective effect of BCG against leprosy and its subtypes: a case-control study in southern Vietnam. Int J Lepr Other Mycobact Dis 1994;62:532-538.

42. Rodríguez ML, Silva SA, Neto JC, de Andrade AL, Martelli CM, Zicker F. Protective effect of intradermal BCG against leprosy: a case-control study in central Brazil. Int J Lepr Other Mycobact Dis 1992;60:335-339.

43. Kerr-Pontes LR, Barreto ML, Evangelista CM, Rodrigues LC, Heukelbach J, Feldmeier H. Socioeconomic, environmental, and behavioural risk factors for leprosy in North-east Brazil: results of a case-control study. Int J Epidemiol 2006;35:994-1000.

44. Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Gonçalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol 2008;15:101-105.

45. Convit J, Smith PG, Zuniga M, Sampson C, Ulrich M, Plata JA, et al. BCG vaccination protects against leprosy in Venezuela: a case-control study. Int J Lepr Other Mycobact Dis 1993;61:185-191.

46. Rahete NP, Zodpey SP, Shrikhande SN, Salodkar AD, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Raipur, India. Indian J Public Health 2007;51:86-90.

47. Zodpey SP, Shrikhande SN, Kulkarni SW, Maldhure BR. Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case-control study. Indian J Public Health 2007;51:184-189.

48. Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev 1999;70:287-294.